Research Articles Library
Literature Analysis Tools
Advanced Search
Filter by PMID, year, source, DOI and other criteria
Literature Analysis
Analyze research trends and hotspots
Batch Export
Export search results to Excel/PDF
Intestinal Ultrasound-Ready to Use for Early Prediction of Disease Course in IBD?
Publication Year: 2024 Source: J Crohns Colitis PMID: 38768180 DOI: 10.1093/ecco-jcc/jjae069
No Abstract
Characteristics of lipid metabolism after treatment of colon cancer mice with American ginseng vesicles
Publication Year: 2024 Source: Phytochem Anal PMID: 38768606 DOI: 10.1002/pca.3367
INTRODUCTION: Lipid molecules are present in tumours and play an important role in the anti-inflammatory response as well as in antiviral protection. Changes in the type and location of lipids in the intestine following exposure to environmental stressors play an important role in several disorders, including ulcerative colitis (UC), inflammatory …
Inflammatory bowel disease has no borders: engaging patients as partners to deliver global, equitable and holistic health care
Publication Year: 2024 Source: Lancet PMID: 38768627 DOI: 10.1016/S0140-6736(24)00983-8
No Abstract
Anxiolytic effects of Enterococcus faecalis 2001 on a mouse model of colitis
Publication Year: 2024 Source: Sci Rep PMID: 38769131
No Abstract
Role of AKR1B10 in inflammatory diseases
Publication Year: 2024 Source: Scand J Immunol PMID: 38769661 DOI: 10.1111/sji.13390
Inflammation is an important pathophysiological process in many diseases; it has beneficial and harmful effects. When exposed to various stimuli, the body triggers an inflammatory response to eliminate invaded pathogens and damaged tissues to maintain homeostasis. However, uncontrollable persistent or excessive inflammatory responses may damage tissues and induce various diseases, …
Novel approaches in IBD therapy: targeting the gut microbiota-bile acid axis
Publication Year: 2024 Source: Gut Microbes PMID: 38769683 DOI: 10.1080/19490976.2024.2356284
Inflammatory bowel disease (IBD) is a chronic and recurrent condition affecting the gastrointestinal tract. Disturbed gut microbiota and abnormal bile acid (BA) metabolism are notable in IBD, suggesting a bidirectional relationship. Specifically, the diversity of the gut microbiota influences BA composition, whereas altered BA profiles can disrupt the microbiota. IBD …
Two-component system RstAB promotes the pathogenicity of adherent-invasive Escherichia coli in response to acidic conditions within macrophages
Publication Year: 2024 Source: Gut Microbes PMID: 38769708
No Abstract
Safety, tolerability, and pharmacokinetics of single- and multiple-ascending doses of olamkicept: Results from randomized, placebo-controlled, first-in-human phase I trials
Publication Year: 2024 Source: Clin Transl Sci PMID: 38769747 DOI: 10.1111/cts.13832
Olamkicept selectively inhibits the cytokine interleukin-6 (IL-6) trans-signaling pathway without blocking the classic pathway and is a promising immunoregulatory therapy for inflammatory bowel disease (IBD). These first-in-human, randomized, placebo-controlled, single- (SAD) and multiple-ascending dose (MAD) trials evaluated olamkicept safety, tolerability, pharmacokinetic, and pharmacodynamic characteristics. Doses tested in the SAD trial …
Standardizing steroid protocols for newly diagnosed inflammatory bowel disease patients: A quality improvement initiative
Publication Year: 2024 Source: J Pediatr Gastroenterol Nutr PMID: 38769760 DOI: 10.1002/jpn3.12246
OBJECTIVES: Systemic steroids can be used for induction of inflammatory bowel disease (IBD), but are not recommended as long-term therapy. Steroid weaning requires rigorous monitoring of symptoms, which may be cumbersome and lead to missed opportunities. We aim to describe our local quality improvement (QI) initiative to improve and standardize …
Neurological disorders following the use of tumor necrosis factor-α inhibitors in inflammatory bowel disease patients: a real-world pharmacovigilance analysis
Publication Year: 2024 Source: Expert Opin Drug Saf PMID: 38769926 DOI: 10.1080/14740338.2024.2357748
BACKGROUND: Tumor necrosis factor-alpha inhibitors (TNFis) are used for the treatment of inflammatory bowel disease (IBD). The aim of this study was to evaluate the association between neurological adverse events (AEs) and TNFi use. METHODS: Data of TNFis indicated for IBD were collected from the Food and Drug Administration Adverse …
Need more literature?
The current database contains 98453 research articles. If you need to search for more literature or perform AI analysis, please use our knowledge acquisition module or explore external literature resources.
External Resources: Access comprehensive literature databases worldwide